Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Total 13F shares
-
8,632,498
-
Share change
-
+3,960,204
-
Total reported value
-
$18,126,749
-
Price per share
-
$2.10
-
Number of holders
-
26
-
Value change
-
+$8,211,937
-
Number of buys
-
14
-
Number of sells
-
11
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q1 2018
As of 31 Mar 2018,
Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,632,498 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, VANGUARD GROUP INC, BlackRock Inc., Artal Group S.A., BRIDGEWAY CAPITAL MANAGEMENT INC, NORTHERN TRUST CORP, Destination Wealth Management, GOLDMAN SACHS GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, and STATE STREET CORP.
This page lists
26
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.